enGene (NASDAQ:ENGN) Issues Earnings Results

enGene (NASDAQ:ENGN) released its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04), FiscalAI reports.

Here are the key takeaways from enGene’s conference call:

• enGene reported $266 million in cash, which management says should fund operations through the planned late-2026 BLA filing and anticipated approval in 2027.
• Interim LEGEND data showed a 54% complete response rate at any time and approximately 25% projected 12-month complete response, with very low treatment interruption or discontinuation of 2.4%; however, durability data remain immature and the statistical analysis plan is not yet finalized.
• Management believes detalimogene is particularly well positioned for community urologists because it can be stored and administered relatively easily, requires no special viral-handling infrastructure, and has a favorable tolerability profile.
• The company remains on track for a fourth-quarter pre-BLA meeting and emphasized that its manufacturing validation runs are complete, potentially reducing regulatory risk in an area where recent oncology approvals have faced manufacturing-related setbacks.
• A surfactant combination cohort completed its safety run-in without dose-limiting toxicities; management expects the approach could improve drug expression, efficacy, durability, and treatment convenience, though clinical benefits remain unproven.

enGene Trading Down 3.6%

ENGN stock opened at $1.85 on Thursday. The company has a market cap of $123.93 million, a P/E ratio of -1.64 and a beta of -0.28. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The company has a quick ratio of 12.57, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average of $1.83 and a 200-day moving average of $3.99.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ENGN. Siren L.L.C. acquired a new position in enGene in the fourth quarter valued at approximately $30,126,000. Braidwell LP boosted its position in shares of enGene by 38.2% in the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock worth $28,276,000 after purchasing an additional 865,000 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of enGene during the fourth quarter worth $17,110,000. MPM Bioimpact LLC boosted its stake in enGene by 247.1% during the 4th quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock worth $16,623,000 after acquiring an additional 1,310,599 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of enGene by 7,214.0% in the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock valued at $13,541,000 after buying an additional 1,479,018 shares during the period. Institutional investors own 64.16% of the company’s stock.

More enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: enGene said it is advancing detalimogene toward a potential Biologics License Application (BLA), with an update from the pivotal LEGEND study expected in the fourth quarter of 2026. The company also plans to engage with the FDA regarding a BLA filing, creating a significant upcoming clinical and regulatory catalyst. EnGene Advances Detalimogene Toward BLA With LEGEND Data Update Planned For Q4 2026
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $4.00 price target, implying approximately 116% potential upside from the reported $1.85 share price. The target reflects expectations that clinical and regulatory progress could materially improve the company’s valuation.
• Neutral Sentiment: Citizens JMP reaffirmed a “market perform” rating. The decision suggests the firm sees limited immediate conviction while investors await additional LEGEND data and regulatory clarity. EnGene Market Perform Rating Reaffirmed
• Negative Sentiment: enGene reported a third-quarter loss of $0.47 per share, wider than the consensus estimate of a $0.43 loss. The earnings miss highlights the company’s ongoing cash-burn and development-stage risks, although management continues to focus on advancing detalimogene and preparing for potential FDA discussions. EnGene Reports Third Quarter 2026 Financial Results and Provides Business Update

Wall Street Analyst Weigh In

ENGN has been the subject of several recent analyst reports. Morgan Stanley lowered shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a report on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of enGene in a research report on Tuesday. Citigroup reissued a “market perform” rating on shares of enGene in a research note on Wednesday. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $11.05.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.